Teknova Announces $15.4 Million Private Placement
Teknova (Nasdaq: TKNO) announced a $15.4 million private placement of 12,385,883 shares of common stock at $1.24 per share, based on the Nasdaq Official Closing Price on July 11, 2024. The private placement is set to close around July 12, 2024, contingent on standard closing conditions. Gross proceeds will be approximately $15.4 million before expenses, and the net proceeds will be used for general corporate purposes. This private placement is not registered under the Securities Act of 1933 but will comply with SEC regulations for resale. Teknova plans to file a registration statement with the SEC within 45 days and aims for it to be effective within 120 days if reviewed by the SEC.
- None.
- Potential shareholder dilution due to the issuance of 12,385,883 new shares.
Insights
Teknova's announcement of a private placement valued at
From a financial standpoint, this private placement reflects Teknova's need for liquidity, possibly hinting at near-term operational or strategic investments. The company’s choice to use net proceeds for general corporate purposes rather than specific projects might imply either flexibility in deploying funds or a lack of immediate, lucrative opportunities. Investors should watch how these funds are allocated over time.
It's important to monitor the company's quarterly earnings and any shifts in operational costs post-placement. A company’s ability to judiciously manage and utilize additional capital is critical for sustained growth and investor confidence.
The legal framework of Teknova’s private placement under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D showcases a well-structured offering exempt from public registration requirements. This allows Teknova to raise funds more rapidly and with fewer regulatory hurdles. The decision to file a registration statement with the SEC within 45 days for resale purposes is a positive step, promoting liquidity and investor transparency.
For investors, the regulatory compliance and adherence to statutory guidelines are reassuring, as they minimize the risk of legal complications. Investors should also be aware that the resale of these securities in the U.S. is contingent on registration or applicable exemptions, impacting liquidity until the SEC registration is approved.
In the context of securities law, this proactive approach to filing a resale registration statement aligns with best practices, ensuring that investor interests are safeguarded while also enhancing the credibility of Teknova’s management team.
HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 of its shares of common stock in a private placement at a purchase price of
The private placement is expected to close on or about July 12, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds to Teknova from the private placement are expected to be approximately
The offer and sale of the securities in the private placement are being made in transactions not involving a public offering and have not been registered pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506(b) of Regulation D promulgated thereunder and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities in the private placement may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
Teknova has agreed to file an initial registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale of the securities to be issued in the private placement no later than 45 days following the date of the definitive agreement and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 120 days after the date of the definitive agreement in the event of a “full review” by the SEC.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers, reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, Teknova’s expectations regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the anticipated use of proceeds from the offering and the timing of filing and effectiveness of any registration statement. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering; demand for Teknova’s products (including the potential delay or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the SEC, including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
FAQ
What is the amount raised by Teknova in the private placement?
How many shares did Teknova issue in the private placement?
At what price were Teknova's shares sold in the private placement?
When is the private placement expected to close?
What does Teknova plan to do with the proceeds from the private placement?
Under which regulations were the securities in Teknova's private placement offered?
Will the shares issued in Teknova's private placement be registered with the SEC?
